JP2010539190A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010539190A5 JP2010539190A5 JP2010525108A JP2010525108A JP2010539190A5 JP 2010539190 A5 JP2010539190 A5 JP 2010539190A5 JP 2010525108 A JP2010525108 A JP 2010525108A JP 2010525108 A JP2010525108 A JP 2010525108A JP 2010539190 A5 JP2010539190 A5 JP 2010539190A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- cdr
- nos
- bone
- cdr sequences
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102100024952 Protein CBFA2T1 Human genes 0.000 claims 35
- 206010065687 Bone loss Diseases 0.000 claims 25
- 102000019307 Sclerostin Human genes 0.000 claims 17
- 108050006698 Sclerostin Proteins 0.000 claims 17
- 210000000988 bone and bone Anatomy 0.000 claims 14
- 210000002966 serum Anatomy 0.000 claims 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 11
- 239000000126 substance Substances 0.000 claims 11
- 230000037182 bone density Effects 0.000 claims 10
- 239000012634 fragment Substances 0.000 claims 9
- 208000035475 disorder Diseases 0.000 claims 7
- 239000003814 drug Substances 0.000 claims 7
- 102000004067 Osteocalcin Human genes 0.000 claims 6
- 108090000573 Osteocalcin Proteins 0.000 claims 6
- 238000004519 manufacturing process Methods 0.000 claims 6
- 208000001132 Osteoporosis Diseases 0.000 claims 5
- 230000032683 aging Effects 0.000 claims 5
- 238000002512 chemotherapy Methods 0.000 claims 5
- 238000002203 pretreatment Methods 0.000 claims 5
- 208000037147 Hypercalcaemia Diseases 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 230000000148 hypercalcaemia Effects 0.000 claims 4
- 208000030915 hypercalcemia disease Diseases 0.000 claims 4
- 102000002260 Alkaline Phosphatase Human genes 0.000 claims 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 claims 3
- 208000013038 Hypocalcemia Diseases 0.000 claims 3
- 230000000705 hypocalcaemia Effects 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 208000011580 syndromic disease Diseases 0.000 claims 3
- 108010022452 Collagen Type I Proteins 0.000 claims 2
- 102000012422 Collagen Type I Human genes 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 206010020707 Hyperparathyroidism primary Diseases 0.000 claims 2
- 208000029725 Metabolic bone disease Diseases 0.000 claims 2
- LOJFGJZQOKTUBR-XAQOOIOESA-N NC(N)=NCCC[C@@H](C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCC(O)=O)C)CC1=CN=CN1 Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCC(O)=O)C)CC1=CN=CN1 LOJFGJZQOKTUBR-XAQOOIOESA-N 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 201000000981 Primary Hyperparathyroidism Diseases 0.000 claims 2
- 108010050808 Procollagen Proteins 0.000 claims 2
- 208000005770 Secondary Hyperparathyroidism Diseases 0.000 claims 2
- 208000007502 anemia Diseases 0.000 claims 2
- 239000011230 binding agent Substances 0.000 claims 2
- 108010049937 collagen type I trimeric cross-linked peptide Proteins 0.000 claims 2
- 210000003054 facial bone Anatomy 0.000 claims 2
- 210000003811 finger Anatomy 0.000 claims 2
- 239000005556 hormone Substances 0.000 claims 2
- 229940088597 hormone Drugs 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 230000000977 initiatory effect Effects 0.000 claims 2
- 230000011164 ossification Effects 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 208000007056 sickle cell anemia Diseases 0.000 claims 2
- 210000003625 skull Anatomy 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 210000002303 tibia Anatomy 0.000 claims 2
- 210000003857 wrist joint Anatomy 0.000 claims 2
- 206010000599 Acromegaly Diseases 0.000 claims 1
- 208000007848 Alcoholism Diseases 0.000 claims 1
- 201000000736 Amenorrhea Diseases 0.000 claims 1
- 206010001928 Amenorrhoea Diseases 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 206010004485 Berylliosis Diseases 0.000 claims 1
- 229940122361 Bisphosphonate Drugs 0.000 claims 1
- 208000006386 Bone Resorption Diseases 0.000 claims 1
- 208000020084 Bone disease Diseases 0.000 claims 1
- 201000003274 CINCA syndrome Diseases 0.000 claims 1
- 206010006956 Calcium deficiency Diseases 0.000 claims 1
- 241000222122 Candida albicans Species 0.000 claims 1
- 206010007134 Candida infections Diseases 0.000 claims 1
- 208000013725 Chronic Kidney Disease-Mineral and Bone disease Diseases 0.000 claims 1
- 241000223205 Coccidioides immitis Species 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 108010035532 Collagen Proteins 0.000 claims 1
- 102000008186 Collagen Human genes 0.000 claims 1
- 208000013586 Complex regional pain syndrome type 1 Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 201000010374 Down Syndrome Diseases 0.000 claims 1
- 206010058314 Dysplasia Diseases 0.000 claims 1
- 208000024720 Fabry Disease Diseases 0.000 claims 1
- 208000015872 Gaucher disease Diseases 0.000 claims 1
- 206010018691 Granuloma Diseases 0.000 claims 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims 1
- 108010051696 Growth Hormone Proteins 0.000 claims 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims 1
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 claims 1
- 201000002563 Histoplasmosis Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 241000282412 Homo Species 0.000 claims 1
- 206010020669 Hypermagnesaemia Diseases 0.000 claims 1
- 206010020850 Hyperthyroidism Diseases 0.000 claims 1
- 206010050977 Hypocalciuria Diseases 0.000 claims 1
- 206010058359 Hypogonadism Diseases 0.000 claims 1
- 208000000038 Hypoparathyroidism Diseases 0.000 claims 1
- 206010021143 Hypoxia Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000017670 Juvenile Paget disease Diseases 0.000 claims 1
- 201000005099 Langerhans cell histiocytosis Diseases 0.000 claims 1
- 208000027414 Legg-Calve-Perthes disease Diseases 0.000 claims 1
- 206010024229 Leprosy Diseases 0.000 claims 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims 1
- 208000002720 Malnutrition Diseases 0.000 claims 1
- 208000030136 Marchiafava-Bignami Disease Diseases 0.000 claims 1
- 208000001826 Marfan syndrome Diseases 0.000 claims 1
- 208000008948 Menkes Kinky Hair Syndrome Diseases 0.000 claims 1
- 208000012583 Menkes disease Diseases 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 208000002678 Mucopolysaccharidoses Diseases 0.000 claims 1
- 208000003452 Multiple Hereditary Exostoses Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000009905 Neurofibromatoses Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 206010031243 Osteogenesis imperfecta Diseases 0.000 claims 1
- 206010031252 Osteomyelitis Diseases 0.000 claims 1
- 206010031264 Osteonecrosis Diseases 0.000 claims 1
- 206010049088 Osteopenia Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 206010033647 Pancreatitis acute Diseases 0.000 claims 1
- 102000003982 Parathyroid hormone Human genes 0.000 claims 1
- 108090000445 Parathyroid hormone Proteins 0.000 claims 1
- 208000010067 Pituitary ACTH Hypersecretion Diseases 0.000 claims 1
- 208000020627 Pituitary-dependent Cushing syndrome Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010035664 Pneumonia Diseases 0.000 claims 1
- 201000001947 Reflex Sympathetic Dystrophy Diseases 0.000 claims 1
- 208000001647 Renal Insufficiency Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 102100038803 Somatotropin Human genes 0.000 claims 1
- 229940121792 Thiazide diuretic Drugs 0.000 claims 1
- 208000024799 Thyroid disease Diseases 0.000 claims 1
- 208000026928 Turner syndrome Diseases 0.000 claims 1
- 208000025865 Ulcer Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 206010047623 Vitamin C deficiency Diseases 0.000 claims 1
- 206010047626 Vitamin D Deficiency Diseases 0.000 claims 1
- 208000018839 Wilson disease Diseases 0.000 claims 1
- 208000008321 Winchester syndrome Diseases 0.000 claims 1
- 201000003229 acute pancreatitis Diseases 0.000 claims 1
- 208000022567 adolescent idiopathic scoliosis Diseases 0.000 claims 1
- 201000007930 alcohol dependence Diseases 0.000 claims 1
- 231100000540 amenorrhea Toxicity 0.000 claims 1
- 208000022531 anorexia Diseases 0.000 claims 1
- 239000001961 anticonvulsive agent Substances 0.000 claims 1
- 229960003965 antiepileptics Drugs 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 150000004663 bisphosphonates Chemical class 0.000 claims 1
- 208000015322 bone marrow disease Diseases 0.000 claims 1
- 230000024279 bone resorption Effects 0.000 claims 1
- 244000309466 calf Species 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 201000003984 candidiasis Diseases 0.000 claims 1
- 210000000845 cartilage Anatomy 0.000 claims 1
- 230000009920 chelation Effects 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000020832 chronic kidney disease Diseases 0.000 claims 1
- 201000003486 coccidioidomycosis Diseases 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 229920001436 collagen Polymers 0.000 claims 1
- 208000022993 cryopyrin-associated periodic syndrome Diseases 0.000 claims 1
- 206010061428 decreased appetite Diseases 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 239000003862 glucocorticoid Substances 0.000 claims 1
- 239000000122 growth hormone Substances 0.000 claims 1
- 229960002897 heparin Drugs 0.000 claims 1
- 229920000669 heparin Polymers 0.000 claims 1
- 235000003642 hunger Nutrition 0.000 claims 1
- 201000005991 hyperphosphatemia Diseases 0.000 claims 1
- 208000011111 hypophosphatemic rickets Diseases 0.000 claims 1
- 230000007954 hypoxia Effects 0.000 claims 1
- 230000006698 induction Effects 0.000 claims 1
- 208000024884 ischemic bone disease Diseases 0.000 claims 1
- 210000001503 joint Anatomy 0.000 claims 1
- 208000018937 joint inflammation Diseases 0.000 claims 1
- 230000000366 juvenile effect Effects 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 210000002414 leg Anatomy 0.000 claims 1
- 230000003902 lesion Effects 0.000 claims 1
- 229910052744 lithium Inorganic materials 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 229910052749 magnesium Inorganic materials 0.000 claims 1
- 239000011777 magnesium Substances 0.000 claims 1
- 230000001071 malnutrition Effects 0.000 claims 1
- 235000000824 malnutrition Nutrition 0.000 claims 1
- 239000004579 marble Substances 0.000 claims 1
- 239000003550 marker Substances 0.000 claims 1
- 208000008585 mastocytosis Diseases 0.000 claims 1
- 230000005906 menstruation Effects 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 230000001617 migratory effect Effects 0.000 claims 1
- 206010028093 mucopolysaccharidosis Diseases 0.000 claims 1
- 208000029522 neoplastic syndrome Diseases 0.000 claims 1
- 201000004931 neurofibromatosis Diseases 0.000 claims 1
- 208000015380 nutritional deficiency disease Diseases 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 210000000963 osteoblast Anatomy 0.000 claims 1
- 208000005368 osteomalacia Diseases 0.000 claims 1
- 208000029985 osteonecrosis of the jaw Diseases 0.000 claims 1
- 230000000849 parathyroid Effects 0.000 claims 1
- 239000000199 parathyroid hormone Substances 0.000 claims 1
- 229960001319 parathyroid hormone Drugs 0.000 claims 1
- 208000028169 periodontal disease Diseases 0.000 claims 1
- 229920001296 polysiloxane Polymers 0.000 claims 1
- 208000001685 postmenopausal osteoporosis Diseases 0.000 claims 1
- 230000035935 pregnancy Effects 0.000 claims 1
- 208000006078 pseudohypoparathyroidism Diseases 0.000 claims 1
- 201000006409 renal osteodystrophy Diseases 0.000 claims 1
- 238000002271 resection Methods 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 230000002784 sclerotic effect Effects 0.000 claims 1
- 208000010233 scurvy Diseases 0.000 claims 1
- 230000037351 starvation Effects 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 230000001629 suppression Effects 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 239000003451 thiazide diuretic agent Substances 0.000 claims 1
- 201000008827 tuberculosis Diseases 0.000 claims 1
- 231100000397 ulcer Toxicity 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97302407P | 2007-09-17 | 2007-09-17 | |
| US60/973,024 | 2007-09-17 | ||
| PCT/US2008/076679 WO2009039175A2 (en) | 2007-09-17 | 2008-09-17 | Method for inhibiting bone resorption |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014178609A Division JP5764704B2 (ja) | 2007-09-17 | 2014-09-03 | 骨吸収の阻害方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010539190A JP2010539190A (ja) | 2010-12-16 |
| JP2010539190A5 true JP2010539190A5 (enExample) | 2011-11-10 |
| JP5643094B2 JP5643094B2 (ja) | 2014-12-17 |
Family
ID=40371592
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010525108A Active JP5643094B2 (ja) | 2007-09-17 | 2008-09-17 | 骨吸収の阻害方法 |
| JP2014178609A Active JP5764704B2 (ja) | 2007-09-17 | 2014-09-03 | 骨吸収の阻害方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014178609A Active JP5764704B2 (ja) | 2007-09-17 | 2014-09-03 | 骨吸収の阻害方法 |
Country Status (20)
| Country | Link |
|---|---|
| US (7) | US8017120B2 (enExample) |
| EP (5) | EP3085386B1 (enExample) |
| JP (2) | JP5643094B2 (enExample) |
| AR (2) | AR068471A1 (enExample) |
| AU (1) | AU2008302313C1 (enExample) |
| CA (2) | CA3170836A1 (enExample) |
| CL (1) | CL2008002775A1 (enExample) |
| CY (3) | CY1114961T1 (enExample) |
| DK (4) | DK2195026T3 (enExample) |
| ES (4) | ES2975587T3 (enExample) |
| FI (1) | FI3725329T3 (enExample) |
| HR (4) | HRP20140153T1 (enExample) |
| HU (3) | HUE050653T2 (enExample) |
| LT (3) | LT3725329T (enExample) |
| MX (1) | MX2010002971A (enExample) |
| PL (4) | PL3725329T3 (enExample) |
| PT (4) | PT3085386T (enExample) |
| SI (4) | SI2195026T1 (enExample) |
| TW (2) | TWI526222B (enExample) |
| WO (1) | WO2009039175A2 (enExample) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1721979B1 (en) | 1998-11-27 | 2010-09-15 | Ucb, S.A. | Compositions and methods for increasing bone mineralisation |
| NO345763B1 (no) | 2003-06-16 | 2021-07-19 | Celltech R&D Inc | Immunogen og antistoffer spesifikke for sklerostin, samt farmasøytiske preparater for å øke benmineralisering. |
| US8003108B2 (en) | 2005-05-03 | 2011-08-23 | Amgen Inc. | Sclerostin epitopes |
| US7592429B2 (en) | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
| EP2423226A3 (en) * | 2006-11-10 | 2012-05-30 | Amgen Inc. | Antibody-based diagnostics and therapeutics |
| WO2008133722A2 (en) * | 2006-11-10 | 2008-11-06 | Ucb Pharma S.A. | Anti human sclerostin antibodies |
| PL3345607T3 (pl) | 2006-12-29 | 2023-01-09 | Ossifi-Mab Llc | Sposoby modyfikowania wzrostu kości poprzez podanie antagonisty lub agonisty sost lub wise |
| CL2008002775A1 (es) | 2007-09-17 | 2008-11-07 | Amgen Inc | Uso de un agente de unión a esclerostina para inhibir la resorción ósea. |
| TWI489993B (zh) | 2007-10-12 | 2015-07-01 | Novartis Ag | 骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法 |
| US20090142766A1 (en) * | 2007-11-09 | 2009-06-04 | Washington University In St. Louis | Methods for measuring the metabolism of cns derived biomolecules in vivo |
| MX2010006519A (es) * | 2007-12-14 | 2010-10-15 | Amgen Inc | Metodo para tratar una fractura de hueso con anticuerpos anti-esclerostina. |
| CA2721052C (en) | 2008-04-11 | 2023-02-21 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
| SMT202000095T1 (it) | 2010-05-14 | 2020-03-13 | Amgen Inc | Formulazioni di anticorpi anti-sclerostina ad alta concentrazione |
| CA2813849C (en) | 2010-11-05 | 2021-06-15 | Novartis Ag | Secukinumab for use in the treatment of ankylosing spondylitis |
| US20140234340A1 (en) | 2010-11-30 | 2014-08-21 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly |
| US20140037638A1 (en) * | 2010-12-02 | 2014-02-06 | The Washington University | Compositions and methods for treating amyloid plaque associated symptoms |
| MX2013010011A (es) | 2011-03-01 | 2014-10-24 | Amgen Inc | Agentes de unión biespecífica. |
| SG193610A1 (en) | 2011-03-25 | 2013-11-29 | Amgen Inc | Anti - sclerostin antibody crystals and formulations thereof |
| ES2823240T3 (es) * | 2011-04-19 | 2021-05-06 | Amgen Inc | Método para el tratamiento de la osteoporosis |
| WO2012149246A1 (en) | 2011-04-29 | 2012-11-01 | Novartis Ag | Methods of treating squamous cell carcinoma related applications |
| PT2739311T (pt) * | 2011-08-04 | 2018-03-26 | Amgen Inc | Método para tratamento de defeitos de lacunas ósseas |
| WO2013043840A1 (en) * | 2011-09-22 | 2013-03-28 | Exelixis, Inc. | Method for treating osteoporosis |
| CN104039828B (zh) | 2011-12-28 | 2017-07-21 | 安进公司 | 通过使用抗骨硬化蛋白抗体治疗牙槽骨流失的方法 |
| EP3626267A1 (en) | 2012-07-05 | 2020-03-25 | UCB Pharma, S.A. | Treatment for bone diseases |
| UY35148A (es) | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
| WO2014118705A1 (en) | 2013-01-31 | 2014-08-07 | Novartis Ag | Methods of treating chronic kidney disease-mineral and bone disorder using sclerostin antagonists |
| WO2014155278A2 (en) | 2013-03-26 | 2014-10-02 | Novartis Ag | Methods of treating autoimmune diseases using il-17 antagonists |
| EP3760235A1 (en) | 2014-09-30 | 2021-01-06 | Washington University | Tau kinetic measurements |
| MA41142A (fr) * | 2014-12-12 | 2017-10-17 | Amgen Inc | Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement |
| AR103173A1 (es) | 2014-12-22 | 2017-04-19 | Novarits Ag | Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17 |
| GB201604124D0 (en) | 2016-03-10 | 2016-04-27 | Ucb Biopharma Sprl | Pharmaceutical formulation |
| JP2020502218A (ja) | 2016-12-21 | 2020-01-23 | メレオ バイオファーマ ３ リミテッド | 骨形成不全症の処置における抗スクレロスチン抗体の使用 |
| IL267430B1 (en) | 2016-12-21 | 2025-09-01 | Mereo Biopharma 3 Ltd | Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta |
| EP3574010A4 (en) | 2017-01-30 | 2020-12-16 | Chugai Seiyaku Kabushiki Kaisha | ANTI-SCLEROSTIN ANTIBODIES AND METHOD OF USE |
| IL316596A (en) * | 2018-03-30 | 2024-12-01 | Amgen Inc | C-terminal antibody variants |
| GB201810746D0 (en) | 2018-06-29 | 2018-08-15 | Mereo Biopharma 3 Ltd | Use of sclerostin antagonist |
| CN111658821A (zh) * | 2020-06-03 | 2020-09-15 | 深圳市百吉因生物科技有限公司 | 负载小干扰rna的胶原基骨修复材料及制备方法及在制备治疗骨质疏松骨折材料中的应用 |
| TW202430215A (zh) | 2022-12-14 | 2024-08-01 | 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 | 用於將治療劑遞送至骨之組成物和方法 |
| WO2025000015A1 (en) * | 2023-06-27 | 2025-01-02 | Perron Institute for Neurological and Translational Science Limited | Antisense oligomer treatment for bone loss |
| WO2025212547A1 (en) * | 2024-04-05 | 2025-10-09 | Amgen Inc. | Methods of treating osteogenesis imperfecta |
Family Cites Families (117)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4331647A (en) * | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
| US4376110A (en) * | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| US4411993A (en) * | 1981-04-29 | 1983-10-25 | Steven Gillis | Hybridoma antibody which inhibits interleukin 2 activity |
| US4427115A (en) * | 1981-10-19 | 1984-01-24 | Laipply Thomas C | One piece alcohol preparation device |
| USRE32011E (en) * | 1981-12-14 | 1985-10-22 | Scripps Clinic And Research Foundation | Ultrapurification of factor VIII using monoclonal antibodies |
| US4543439A (en) * | 1982-12-13 | 1985-09-24 | Massachusetts Institute Of Technology | Production and use of monoclonal antibodies to phosphotyrosine-containing proteins |
| US6054561A (en) * | 1984-02-08 | 2000-04-25 | Chiron Corporation | Antigen-binding sites of antibody molecules specific for cancer antigens |
| DE3417525C1 (de) * | 1984-05-11 | 1986-01-09 | Matter + Siegmann Ag, Wohlen | Vorrichtung zur quantitativen und qualitativen Erfassung von kohlenwasserstoffhaltigen Schwebeteilchen in Gasen |
| US4902614A (en) * | 1984-12-03 | 1990-02-20 | Teijin Limited | Monoclonal antibody to human protein C |
| US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
| KR970010758B1 (ko) | 1987-12-15 | 1997-06-30 | 진 쉬어즈 피티와이. 리미티드 | 올리고리보뉴클레오티드 화합물 |
| US5223409A (en) * | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5571714A (en) | 1988-12-22 | 1996-11-05 | Celtrix Pharmaceuticals, Inc. | Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5549910A (en) * | 1989-03-31 | 1996-08-27 | The Regents Of The University Of California | Preparation of liposome and lipid complex compositions |
| US5244805A (en) | 1989-05-17 | 1993-09-14 | University Of Georgia Research Foundation, Inc. | Baculovirus expression vectors |
| US5177197A (en) | 1990-02-27 | 1993-01-05 | Ludwig Institute For Cancer Research | Isolated nucleotide sequence expressing human transforming growth factor-β1-binding protein |
| US5466468A (en) * | 1990-04-03 | 1995-11-14 | Ciba-Geigy Corporation | Parenterally administrable liposome formulation comprising synthetic lipids |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| JP3218637B2 (ja) * | 1990-07-26 | 2001-10-15 | 大正製薬株式会社 | 安定なリポソーム水懸濁液 |
| EP0542810A1 (en) | 1990-08-02 | 1993-05-26 | B.R. Centre Limited | Methods for the production of proteins with a desired function |
| JP2958076B2 (ja) * | 1990-08-27 | 1999-10-06 | 株式会社ビタミン研究所 | 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法 |
| US5877397A (en) * | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5698426A (en) * | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
| JPH04141095A (ja) | 1990-10-02 | 1992-05-14 | Chemo Sero Therapeut Res Inst | 組換え抗ｈｉｖ改変抗体および改変抗体の調製方法 |
| US5070108A (en) * | 1990-10-12 | 1991-12-03 | Trustees Of The University Of Pennsylvania | Methods of treating osteoporosis, increasing bone mineral content and preventing the occurrence of compression fractures in a mammal |
| CA2094608A1 (en) | 1990-10-22 | 1992-04-23 | John D. Taylor | Dna construct for providing rna therapy |
| US5399363A (en) | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
| US5145684A (en) * | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| JP3370324B2 (ja) | 1991-04-25 | 2003-01-27 | 中外製薬株式会社 | ヒトインターロイキン−６受容体に対する再構成ヒト抗体 |
| US5807683A (en) | 1992-11-19 | 1998-09-15 | Combichem, Inc. | Combinatorial libraries and methods for their use |
| EP0708659A4 (en) * | 1993-06-07 | 2000-08-23 | Genentech Inc | HIV ENVELOPE POLYPEPTIDES |
| US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
| US5453492A (en) * | 1993-07-28 | 1995-09-26 | La Jolla Cancer Research Foundation | 60 kDa transforming growth factor-β-binding protein and its use to detect or purify TGF-β |
| US5837458A (en) * | 1994-02-17 | 1998-11-17 | Maxygen, Inc. | Methods and compositions for cellular and metabolic engineering |
| US5605793A (en) * | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
| AU702163B2 (en) | 1994-04-29 | 1999-02-18 | Creative Biomolecules, Inc. | Morphogenic protein-specific cell surface receptors and uses therefor |
| US5738996A (en) | 1994-06-15 | 1998-04-14 | Pence, Inc. | Combinational library composition and method |
| DE4427221A1 (de) | 1994-08-01 | 1996-02-08 | Gsf Forschungszentrum Umwelt | Retrovirus-induzierte Osteoklasten-Modulation für die Osteoporose-Therapie |
| US5846770A (en) | 1994-11-22 | 1998-12-08 | Genetics Institute, Inc. | DNA molecules encoding human chordin |
| US6057421A (en) * | 1994-11-30 | 2000-05-02 | Immpheron, Inc. | Variable heavy and light chain regions of murine monoclonal antibody 1F7 |
| US5723750A (en) | 1995-01-12 | 1998-03-03 | Vanderbilt University | Transgenic plants expressing disassembly deficient viral coat proteins |
| US5795587A (en) * | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
| IE80468B1 (en) | 1995-04-04 | 1998-07-29 | Elan Corp Plc | Controlled release biodegradable nanoparticles containing insulin |
| CA2220912A1 (en) * | 1995-06-05 | 1996-12-12 | Gregg A. Hastings | Human ccn-like growth factor |
| US5738868A (en) * | 1995-07-18 | 1998-04-14 | Lipogenics Ltd. | Liposome compositions and kits therefor |
| DK0912738T3 (da) * | 1996-05-22 | 2008-11-17 | Viventia Biotech Inc | Antigen-bindende-fragmenter der specifikt detekterer cancerceller, nukleotider der koder fragmenterne og anvendelse deraf til profylakse og detektion af cancere |
| US6133426A (en) * | 1997-02-21 | 2000-10-17 | Genentech, Inc. | Humanized anti-IL-8 monoclonal antibodies |
| US5989909A (en) | 1997-09-26 | 1999-11-23 | Millennium Biotherapeutics, Inc. | Huchordin and uses thereof |
| AU6959898A (en) * | 1997-04-11 | 1998-11-11 | David J. Grainger | Compounds and therapies for the prevention of vascular and non-vascular pathol ogies |
| US6278039B1 (en) | 1997-05-28 | 2001-08-21 | Axys Pharmaceuticals, Inc. | C. elegans deletion mutants |
| EP2380906A2 (en) | 1997-06-12 | 2011-10-26 | Novartis International Pharmaceutical Ltd. | Artificial antibody polypeptides |
| US6075007A (en) | 1997-07-17 | 2000-06-13 | Regeneron Pharmaceuticals, Inc. | Modified noggin polypeptide and compositions |
| AU8555798A (en) | 1997-08-01 | 1999-02-22 | Genset | 5' ests for secreted proteins expressed in muscle and other mesodermal tissues |
| US6815201B2 (en) * | 1997-09-08 | 2004-11-09 | The Public Health Research Institute Of The City Of New York, Inc. | HIV-1 gp120 V1/V2 domain epitopes capable of generating neutralizing antibodies |
| US6251588B1 (en) | 1998-02-10 | 2001-06-26 | Agilent Technologies, Inc. | Method for evaluating oligonucleotide probe sequences |
| GB9818881D0 (en) * | 1998-08-28 | 1998-10-21 | Glaxo Group Ltd | Compounds |
| US6544485B1 (en) * | 2001-01-29 | 2003-04-08 | Sharper Image Corporation | Electro-kinetic device with enhanced anti-microorganism capability |
| EP1721979B1 (en) * | 1998-11-27 | 2010-09-15 | Ucb, S.A. | Compositions and methods for increasing bone mineralisation |
| US20040009535A1 (en) | 1998-11-27 | 2004-01-15 | Celltech R&D, Inc. | Compositions and methods for increasing bone mineralization |
| IL144578A0 (en) | 1999-01-29 | 2002-05-23 | Imclone Systems Inc | Antibodies specific to kdr and uses thereof |
| US6110462A (en) | 1999-03-03 | 2000-08-29 | The Scripps Research Institute | Enzymatic DNA molecules that contain modified nucleotides |
| DE60042799D1 (de) | 1999-06-09 | 2009-10-01 | Genentech Inc | Methoden zur Diagnose von Tumoren |
| US6197592B1 (en) | 1999-07-15 | 2001-03-06 | Bio-Rad Laboratories, Inc. | Clinical control materials for detection of bone resorptive markers |
| JP4141095B2 (ja) | 1999-10-29 | 2008-08-27 | 三洋電機株式会社 | 半導体装置とその製造方法 |
| AU2001241968B2 (en) | 2000-03-02 | 2005-09-15 | Amgen Inc. | Chordin-like-2 molecules and uses thereof |
| JP2003534813A (ja) * | 2000-06-01 | 2003-11-25 | アムジェン インコーポレーテッド | シスチンノットポリペプチド：ｃｌｏａｋｅｄ−２分子およびその使用 |
| WO2001098491A2 (en) | 2000-06-19 | 2001-12-27 | F. Hoffmann-La Roche Ag | Osteolevin gene polymorphisms |
| AU2002216610A1 (en) | 2000-09-01 | 2002-04-02 | Genentech Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| WO2002030463A2 (en) | 2000-10-12 | 2002-04-18 | Genentech, Inc. | Reduced-viscosity concentrated protein formulations |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| CA2374027A1 (en) * | 2001-03-13 | 2002-09-13 | The Minister Of National Defence | Cloning, expression, sequencing, and functional enhancement of monoclonal scfv antibody against venezuelan equine encephalitis virus(vee) |
| DE10145772A1 (de) * | 2001-09-17 | 2003-04-10 | Bayer Cropscience Ag | DELTA·1·-Pyrroline |
| US7261892B2 (en) | 2001-11-27 | 2007-08-28 | Celltech R&D Limited | Methods for diagnosis and treatment of epithelial-derived cancers |
| JP4467304B2 (ja) | 2001-12-06 | 2010-05-26 | バイオコントロール システムズ，インコーポレイティド | サンプル収集および試験システム |
| US20030186915A1 (en) * | 2002-02-11 | 2003-10-02 | Yang Pan | Regulatory polynucleotides and uses thereof |
| CA2476410C (en) | 2002-03-01 | 2013-09-24 | Celltech R & D, Inc. | Methods to increase or decrease bone density |
| WO2003087763A2 (en) | 2002-04-03 | 2003-10-23 | Celltech R & D, Inc. | Association of polymorphisms in the sost gene region with bone mineral density |
| FR2838379B1 (fr) | 2002-04-12 | 2005-06-24 | Valeo Climatisation | Dispositif de purification de l'air de l'habitacle d'un vehicule automobile |
| US7893218B2 (en) * | 2003-06-16 | 2011-02-22 | Stowers Institute For Medical Research | Antibodies that specifically bind SOST peptides |
| AU2003276430A1 (en) * | 2002-06-14 | 2003-12-31 | Stowers Institute For Medical Research | Wise/sost nucleic acid sequences and amino acid sequences |
| JP4976653B2 (ja) | 2002-11-01 | 2012-07-18 | ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンティッド バイ ザ セクレタリー オブ ザ デパートメント オブ ヘルス アンド ヒューマン サービシス | 免疫刺激性ＣｐＧオリゴヌクレオチドを用いてバイオテロ病原体による感染症を予防する方法 |
| EP2314691A3 (en) | 2002-11-14 | 2012-01-18 | Dharmacon, Inc. | Fuctional and hyperfunctional siRNA |
| DE10255152A1 (de) | 2002-11-26 | 2004-06-03 | Von Langen Ursula Lang | Schadstoffsauger |
| US7642238B2 (en) * | 2002-12-05 | 2010-01-05 | Shaughnessy John D | Molecular determinants of myeloma bone disease and uses thereof |
| US20040141875A1 (en) * | 2003-01-15 | 2004-07-22 | Rajiv Doshi | System and method for treating microorganisms within motor vehicle heating, ventilation, and air conditioning units |
| PL1608399T3 (pl) | 2003-03-14 | 2012-09-28 | Ucb Mfg Inc | Kompleks sklerostyny i nogginy lub chordyny, oraz czynniki modulujące tworzenie tego kompleksu |
| JP4605799B2 (ja) | 2003-04-02 | 2011-01-05 | ダーマコン， インコーポレイテッド | Ｒｎａ干渉において使用するための修飾ポリヌクレオチド |
| US20050158303A1 (en) | 2003-04-04 | 2005-07-21 | Genentech, Inc. | Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations |
| CU23403A1 (es) | 2003-04-23 | 2009-08-04 | Centro Inmunologia Molecular | Anticuerpos recombinantes y fragmentos que reconocen el gangliósido n-glicolil gm3 y su uso para diagnóstico y tratamiento de tumores |
| NO345763B1 (no) | 2003-06-16 | 2021-07-19 | Celltech R&D Inc | Immunogen og antistoffer spesifikke for sklerostin, samt farmasøytiske preparater for å øke benmineralisering. |
| US8461155B2 (en) | 2003-09-22 | 2013-06-11 | University Of Connecticut | Sclerostin and the inhibition of WNT signaling and bone formation |
| EP2123759B1 (en) | 2004-02-06 | 2014-01-15 | Thermo Fisher Scientific Biosciences Inc. | Stabilized RNAS as transfection controls and silencing reagents |
| KR101147147B1 (ko) | 2004-04-01 | 2012-05-25 | 머크 샤프 앤드 돔 코포레이션 | Ｒｎａ 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드 |
| US20050267233A1 (en) | 2004-05-25 | 2005-12-01 | Joshi Ashok V | Anti-microbial handle system |
| EP1786837B1 (en) | 2004-08-04 | 2013-05-01 | Amgen Inc., | Antibodies to dkk-1 |
| US8003108B2 (en) * | 2005-05-03 | 2011-08-23 | Amgen Inc. | Sclerostin epitopes |
| US7592429B2 (en) | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
| US8541177B2 (en) * | 2006-01-13 | 2013-09-24 | A Chan Holding B.V. | Treatment and diagnosis of abnormal bone density with an inhibitor of the glypican-sclerostin interaction |
| WO2008133722A2 (en) | 2006-11-10 | 2008-11-06 | Ucb Pharma S.A. | Anti human sclerostin antibodies |
| EP2423226A3 (en) | 2006-11-10 | 2012-05-30 | Amgen Inc. | Antibody-based diagnostics and therapeutics |
| US20080120672A1 (en) | 2006-11-21 | 2008-05-22 | Francesco Caggioni | Methods and Apparatus for Weighted Multicasting of Data Streams |
| PL3345607T3 (pl) | 2006-12-29 | 2023-01-09 | Ossifi-Mab Llc | Sposoby modyfikowania wzrostu kości poprzez podanie antagonisty lub agonisty sost lub wise |
| BRPI0807205A2 (pt) | 2007-02-02 | 2014-07-22 | Novartis Ag | Moduladores de ligantes esclerostina para tratamento de distúrbios relacionados ao osso |
| EP2664346A1 (en) * | 2007-03-20 | 2013-11-20 | Eli Lilly And Co. | Anti-sclerostin antibodies |
| JOP20080381B1 (ar) | 2007-08-23 | 2023-03-28 | Amgen Inc | بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9) |
| CL2008002775A1 (es) | 2007-09-17 | 2008-11-07 | Amgen Inc | Uso de un agente de unión a esclerostina para inhibir la resorción ósea. |
| TWI489993B (zh) | 2007-10-12 | 2015-07-01 | Novartis Ag | 骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法 |
| KR20100091170A (ko) | 2007-11-02 | 2010-08-18 | 노파르티스 아게 | 저밀도-지단백질 수용체-관련 단백질 ６ (ｌｒｐ６)을 조정하기 위한 분자 및 방법 |
| MX2010006519A (es) | 2007-12-14 | 2010-10-15 | Amgen Inc | Metodo para tratar una fractura de hueso con anticuerpos anti-esclerostina. |
| NZ589434A (en) | 2008-06-03 | 2012-11-30 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| AR075715A1 (es) | 2009-03-05 | 2011-04-20 | Novartis Ag | Formulacion de anticuerpo liofilizado |
| WO2010100179A2 (en) | 2009-03-05 | 2010-09-10 | Novartis Ag | Self-forming gel system for sustained drug delivery |
| WO2010115932A1 (en) | 2009-04-08 | 2010-10-14 | Novartis Ag | Combination for the treatment of bone loss |
| WO2010130830A2 (en) | 2009-05-15 | 2010-11-18 | Ablynx N.V. | Amino acid sequences directed against sclerostin and polypeptides comprising the same for the treatment of bone diseases and disorders |
| WO2012028683A1 (en) | 2010-09-02 | 2012-03-08 | Novartis Ag | Antibody gel system for sustained drug delivery |
| EP2632951B1 (en) | 2010-10-27 | 2017-08-02 | Amgen Inc. | Dkk1 antibodies and methods of use |
-
2008
- 2008-09-16 CL CL2008002775A patent/CL2008002775A1/es unknown
- 2008-09-17 LT LTEP20174310.1T patent/LT3725329T/lt unknown
- 2008-09-17 PT PT161620687T patent/PT3085386T/pt unknown
- 2008-09-17 FI FIEP20174310.1T patent/FI3725329T3/fi active
- 2008-09-17 US US12/212,327 patent/US8017120B2/en active Active
- 2008-09-17 AU AU2008302313A patent/AU2008302313C1/en active Active
- 2008-09-17 JP JP2010525108A patent/JP5643094B2/ja active Active
- 2008-09-17 HU HUE16162068A patent/HUE050653T2/hu unknown
- 2008-09-17 AR ARP080104044A patent/AR068471A1/es not_active Application Discontinuation
- 2008-09-17 HU HUE20174310A patent/HUE066466T2/hu unknown
- 2008-09-17 EP EP16162068.7A patent/EP3085386B1/en not_active Revoked
- 2008-09-17 HR HRP20140153AT patent/HRP20140153T1/hr unknown
- 2008-09-17 HU HUE12180292A patent/HUE030168T2/en unknown
- 2008-09-17 HR HRP20240493TT patent/HRP20240493T3/hr unknown
- 2008-09-17 DK DK08832690.5T patent/DK2195026T3/da active
- 2008-09-17 LT LTEP16162068.7T patent/LT3085386T/lt unknown
- 2008-09-17 PL PL20174310.1T patent/PL3725329T3/pl unknown
- 2008-09-17 PT PT121802920T patent/PT2556841T/pt unknown
- 2008-09-17 CA CA3170836A patent/CA3170836A1/en active Pending
- 2008-09-17 EP EP23219258.3A patent/EP4335510A3/en active Pending
- 2008-09-17 PT PT88326905T patent/PT2195026E/pt unknown
- 2008-09-17 MX MX2010002971A patent/MX2010002971A/es active IP Right Grant
- 2008-09-17 PL PL16162068T patent/PL3085386T3/pl unknown
- 2008-09-17 SI SI200831170T patent/SI2195026T1/sl unknown
- 2008-09-17 EP EP20174310.1A patent/EP3725329B1/en active Active
- 2008-09-17 TW TW097135666A patent/TWI526222B/zh active
- 2008-09-17 PL PL08832690T patent/PL2195026T3/pl unknown
- 2008-09-17 SI SI200831663A patent/SI2556841T1/sl unknown
- 2008-09-17 ES ES20174310T patent/ES2975587T3/es active Active
- 2008-09-17 PL PL12180292.0T patent/PL2556841T3/pl unknown
- 2008-09-17 ES ES16162068T patent/ES2815677T3/es active Active
- 2008-09-17 SI SI200832217T patent/SI3725329T1/sl unknown
- 2008-09-17 LT LTEP12180292.0T patent/LT2556841T/lt unknown
- 2008-09-17 EP EP12180292.0A patent/EP2556841B9/en not_active Revoked
- 2008-09-17 EP EP08832690.5A patent/EP2195026B1/en active Active
- 2008-09-17 TW TW104134720A patent/TWI612972B/zh active
- 2008-09-17 ES ES08832690.5T patent/ES2445792T3/es active Active
- 2008-09-17 DK DK16162068.7T patent/DK3085386T3/da active
- 2008-09-17 CA CA2699905A patent/CA2699905C/en active Active
- 2008-09-17 WO PCT/US2008/076679 patent/WO2009039175A2/en not_active Ceased
- 2008-09-17 SI SI200832137T patent/SI3085386T1/sl unknown
- 2008-09-17 PT PT201743101T patent/PT3725329T/pt unknown
- 2008-09-17 ES ES12180292.0T patent/ES2581754T3/es active Active
- 2008-09-17 DK DK12180292.0T patent/DK2556841T3/en active
- 2008-09-17 DK DK20174310.1T patent/DK3725329T3/da active
-
2011
- 2011-04-19 US US13/090,075 patent/US8440193B2/en active Active
- 2011-04-19 US US13/090,058 patent/US8329176B2/en active Active
-
2013
- 2013-04-11 US US13/860,954 patent/US9089553B2/en active Active
-
2014
- 2014-03-07 CY CY20141100183T patent/CY1114961T1/el unknown
- 2014-09-03 JP JP2014178609A patent/JP5764704B2/ja active Active
-
2015
- 2015-06-16 US US14/740,838 patent/US10273293B2/en active Active
-
2016
- 2016-07-14 HR HRP20160872TT patent/HRP20160872T1/hr unknown
- 2016-07-15 CY CY20161100685T patent/CY1117908T1/el unknown
-
2017
- 2017-10-27 AR ARP170103001A patent/AR109995A2/es unknown
-
2018
- 2018-11-14 US US16/191,068 patent/US11091537B2/en active Active
-
2020
- 2020-09-02 CY CY20201100823T patent/CY1123463T1/el unknown
- 2020-09-09 HR HRP20201438TT patent/HRP20201438T1/hr unknown
-
2021
- 2021-07-15 US US17/376,304 patent/US12421304B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010539190A5 (enExample) | ||
| HRP20201438T1 (hr) | Metoda inhibiranja resorpcije kosti | |
| HRP20130803T1 (hr) | Sredstva za vezanje sklerostina | |
| JP7350028B2 (ja) | 骨疾患の治療 | |
| JP2008539726A5 (enExample) | ||
| JP2015524386A5 (enExample) | ||
| HRP20201266T1 (hr) | Anti fg23 antitijelo i farmaceutski pripravak koji sadrži isto | |
| US20240400664A1 (en) | Anti-Sclerostin Antibodies and Their Use to Treat Bone Disorders as Part of a Regimen | |
| HRP20170514T1 (hr) | Epitopi sklerostina | |
| RU2014143770A (ru) | Новое антитело против siglec-15 | |
| US20200115444A1 (en) | Methods for treating bone gap defects | |
| HRP20201366T1 (hr) | Metoda liječenja osteoporoze | |
| HK40014911A (en) | Treatment for bone diseases | |
| HK1196251A (en) | Method for treating bone gap defects |